HIM
BIOTW

HGC Investment Management’s Biotech Acquisition Company Warrant BIOTW Stock Holding History

HGC Investment Management’s Portfolio BIOTW Stock Details BIOTW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,214,583
Closed -$78K – 348
2022
Q4 		$78K Hold
1,214,583
– – 0.01% 229
2022
Q3 		$73K Sell
1,214,583
-1,228,782
-50% -$71.4K ﹤0.01% 272
2022
Q2 		$403K Buy
2,443,365
+1,227,583
+101% +$254K 0.01% 310
2022
Q1 		$292K Buy
1,215,782
+664,832
+121% +$212K 0.02% 269
2021
Q4 		$364K Buy
+550,950
New +$382K 0.02% 277

HGC Investment Management's BIOTW Position: Q1 2023 in Review

HGC Investment Management sold out of Biotech Acquisition Company Warrant (BIOTW) in Q1 2023, closing a stake of 1,214,583 shares — an estimated $78K sold.

HGC Investment Management first reported a position in BIOTW in Q4 2021 and held it in 5 quarters. The position peaked at $403K in Q2 2022. 0 funds tracked by Wall St. Rank hold BIOTW as of Q1 2023.

  • HGC Investment Management reported no remaining Biotech Acquisition Company Warrant position as of Q1 2023 after selling out during the quarter.
  • HGC Investment Management sold 1,214,583 Biotech Acquisition Company Warrant shares in Q1 2023, an estimated $78K.
  • HGC Investment Management first reported a position in Biotech Acquisition Company Warrant in Q4 2021 and held it in 5 quarters.
  • HGC Investment Management's Biotech Acquisition Company Warrant position peaked at $403K in Q2 2022.
  • 0 funds tracked by Wall St. Rank held Biotech Acquisition Company Warrant as of Q1 2023.

Based on HGC Investment Management's 13F filing for Q1 2023, filed 15 May 2023.